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ABSTRACT: Interstitial cystitis/painful bladder syndrome
(IC) is a chronic syndrome of unknown etiology that presents
with bladder pain, urinary frequency, and urgency. The lack of
speciﬁc biomarkers and a poor understanding of underlying
molecular mechanisms present challenges for disease diagnosis
and therapy. The goals of this study were to identify
noninvasive biomarker candidates for IC from urine specimens
and to potentially gain new insight into disease mechanisms
using a nuclear magnetic resonance (NMR)-based global
metabolomics analysis of urine from female IC patients and
controls. Principal component analysis (PCA) suggested that
the urinary metabolome of IC and controls was clearly
diﬀerent, with 140 NMR peaks signiﬁcantly altered in IC
patients (FDR < 0.05) compared to that in controls. On the basis of strong correlation scores, ﬁfteen metabolite peaks were
nominated as the strongest signature of IC. Among those signals that were higher in the IC group, three peaks were annotated as
tyramine, the pain-related neuromodulator. Two peaks were annotated as 2-oxoglutarate. Levels of tyramine and 2-oxoglutarate
were signiﬁcantly elevated in urine specimens of IC subjects. An independent analysis using mass spectrometry also showed
signiﬁcantly increased levels of tyramine and 2-oxoglutarate in IC patients compared to controls. Functional studies showed that
2-oxoglutarate, but not tyramine, retarded growth of normal bladder epithelial cells. These preliminary ﬁndings suggest that
analysis of urine metabolites has promise in biomarker development in the context of IC.
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■ INTRODUCTION
Interstitial cystitis/painful bladder syndrome/bladder pain
syndrome (IC) is a chronic visceral pain syndrome of unknown
etiology that presents with a constellation of symptoms,
including bladder pain, urinary frequency and urgency, and
small voided volumes, in the absence of other identiﬁable
etiologies.1−4 IC is a common condition aﬀecting approximately
1 out of 77 people, which translates into three to eight million
women and one to four million men in the United States alone.
Of those aﬀected, approximately 80% of patients are female. Due
to lack of consistent and eﬀective treatments, the chronic pain
from IC reduces quality of life and generates a great public health
burden. IC results in more than $100 million/year in both direct
healthcare expenses and indirect costs due to reduced
productivity and work performance.
Diagnostic tests for IC include urine cytology, potassium
sensitivity tests (considered outdated), cystoscopy with and
without hydrodistention and/or bladder biopsy, and bioﬂuid-
based assays.5−8 However, cytology is nondiagnostic, and
cystoscopic appearance is often normal in IC patients. Classic
ulcerations of the bladder lining (Hunner’s ulcers) are found in
only 5−10% of patients with IC symptoms, and bladder biopsy is
also often nondiagnostic. Although hydrodistension in patients
with IC demonstrates punctuate bleeding (also called glomer-
ulations), these ﬁndings also occur with hydrodistention of
normal bladders. On the contrary, assays of urine components
are noninvasive and can be easily repeated. Urine is also much
less complex than serum but nevertheless can contain disease
biomarkers.9
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Metabolic proﬁling using nuclear magnetic resonance (NMR)
spectroscopy can provide global chemical ﬁngerprints of the
physiology andmetabolism of cells and can identify physiological
and pathological states of biological samples. NMR proﬁles of
metabolites can be interpreted through computational methods
using multivariate statistical analysis. Metabolomics approaches
have been used to identify biomarkers of disease using urine,
plasma, saliva, fecal extract, and sputum.10−12 These sources
represent noninvasive methods for disease proﬁling and are thus
much preferred to invasive methods.
In this study, we attempted to identify IC-associated
metabolites by NMR using urine specimens from IC patients
and control subjects. Our ﬁndings provide preliminary evidence
that metabolomics analysis of urine can potentially segregate IC
patients from control subjects.
■ MATERIALS AND METHODS
Ethics Statement
This study was approved by the Ethics Committee of Inha
University Hospital in South Korea. Written informed consent
was obtained from all subjects. The Institutional Review Board of
Inha University Hospital approved collection, curation, and
analysis of all samples.
Reagents
Cell culture medium and heat-inactivated and dialyzed fetal
bovine serum were purchased from Invitrogen (Carlsbad, CA).
Crystal violet solution was obtained from Promega (Madison,
WI). All reagents for sample preparation for NMR and liquid
chromatography−mass spectrometry (LC−MS) analysis as well
as tyramine and 2-oxoglutarate were obtained from Sigma-
Aldrich.
Subjects and Urine Specimen Collection
Patients and healthy control subjects were recruited from an
outpatient urology clinic at Inha University Hospital. Workup
included symptom assessment, cystoscopic evaluation, physical
examination, urodynamics, and/or urine culture. Patients with a
history of other diseases (such as any types of cancer,
inﬂammation, or diabetes, etc.) were excluded. All subjects
were of Asian female descent living in South Korea. To avoid
possible contamination with vaginal or urethral cells, ﬁrst
morning urine specimens were obtained using clean catch
methods in a sterile environment. The deidentiﬁed specimens
were centrifuged to remove cell debris, and supernatants were
processed into individual aliquots of 1 mL/tube before storage at
−80 °C until further analysis.
1H NMR Analysis of Urine
1H NMR spectroscopy-based metabolomics analysis was
performed to search for soluble metabolites that segregate with
the diagnosis of IC. The NMR facility at the Korea Basic Science
Institute was used for this study. Sample preparation for 1H
NMR was done as follows: aliquots of urine specimens (500 μL/
each) were resuspended in 50 μL of D2O containing sodium-3-
trimethylsily-[2,2,3,3-2H4]-1-propionate (TSP, 0.025%, w/v) in
a 5 mm NMR tube. An NMR spectrometer (Bruker Biospin,
Avance 500) operating at a proton NMR frequency of 500.13
MHz and equipped with a triple-resonance cryogenic probe was
used for these experiments. All one-dimensional spectra of the
urine samples were measured.
Data Processing
The NMR data in urine samples from IC patients and healthy
subjects were preprocessed as previously described.13 We
excluded one subject from the IC patient group and three
subjects from the control group because their spectra were
outliers based on PCA analysis. Fourier transformation and
phase and baseline correction of the time domain data were
manually performed. The resulting frequency domain data were
binned at a 0.002 ppm interval. The signals were normalized
against total integration values and 0.025% TSP. The region
corresponding to water (4.6−5.0 ppm) was removed from all
spectra. Data pretreatment including baseline correction,
chromatogram alignment, time-window setting, hierarchical
multivariate curve resolution, H-MCR, and normalization were
performed in MATLAB (version 7.3) using custom scripts.
Identiﬁcation of detected NMR spectra was performed using
VNMRS500 (Varian Inc.). The metabolites were identiﬁed by a
database search, based on spectra and chromatographic retention
index, using Chenomx (spectral database; Edmonton, Alberta,
Canada) by ﬁtting the experimental spectra to those in the
database.
Identiﬁcation of Metabolic Marker Candidates
To identify potential metabolites as marker candidates that can
discriminate IC patients from healthy subjects, we applied a two-
step approach. First, a nonparametric Wilcoxon rank sum test
was performed to extract signiﬁcant features from normalized
NMR data. Second, the resultant NMR peak proﬁles, which
contain proﬁles of 140 variables, were then imported into
MetaboAnalyst, version 2.0.14 Mean-centering with Pareto
scaling was performed prior to multivariate statistical analysis.
Partial least-squares discriminant analysis (PLS-DA), important
variable selection with sum of absolute regression coeﬃcient, and
model evaluation with permutation strategy were carried out
according to a published protocol.15
Liquid Chromatography−Mass Spectrometry (LC−MS or
Alternatively HPLC−MS)
For LC−MS analysis, the supernatant of centrifuged urine
samples was directly injected with an injection volume of 5 μL.
HPLC was performed on an Agilent 1100 series liquid
chromatography (Agilent, CO). The chromatographic separa-
tion was performed on a Zic-Philic Polymeric Beads Peek
Column (150 × 2.1 mm, 5 μm, Merck kGaA, Darmstadt,
Germany) at 35 °C. Mobile phases A and B were DW with 10
mM ammonium carbonate (pH 9.0) and acetonitrile,
respectively. The mobile phase was delivered at a ﬂow-rate of
0.15 mL/min. The linear gradient was as follows: 80% B at 0 min,
35% B at 10 min, 5% B at 12 min, 5% B at 25 min, 80% B at 25.1
min, and 80% B at 35 min. An API 2000 mass spectrometer
controlled by the Analyst 1.6 software (AB/SCIEX, Framing-
ham, MA) and equipped with an electrospray ionization (ESI)
source was used in positive ion mode for detecting tyramine and
in negative ion mode for detecting 2-oxoglutarate. For mass
detection, multiple reaction monitoring (MRM) was performed
with the m/z value of parent and fragment ions. The MRM
transitions were 138 > 121 (tyramine) in positive ion mode and
145 > 101 (2-oxoglutarate) in negative ion mode. Two samples
were excluded from the LC−MS analysis because of their
abnormal detection levels.
Cell Culture and Proliferation Assay
Immortalized normal human bladder epithelial cells, TRT-HU1,
were maintained as described previously.16 TRT-HU1 cells were
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seeded in 24-well culture plates at a density of 1 × 102 cells per
well in standard growth medium. For the next 3 days, the cells
were treated with varying doses of tyramine or 2-oxoglutarate.
Crystal violet staining analysis was performed for determination
of cell proliferation.16
■ RESULTS
Characteristics of the Study Subjects
The Inha Institutional Review Board approved collection and
analysis of all samples (IUH-IRB no. 10-0751). All patients and
healthy control subjects were recruited for this study from an
outpatient urology clinic at Inha University Hospital (South
Korea). A clinical diagnosis of IC was made by two independent
urologists (T.L. and S.P.) according to NIDDK criteria (e.g.,
frequency, urgency, bladder pain, discomfort, and the presence of
glomerulations during cystoscopic hydrodistention) before any
treatment or medication was given. In total, we enrolled 64
female subjects (43 IC patients and 21 normal subjects) with a
mean age of around 51. Population-based, age-matched controls
were recruited from one clinic using the same standard operating
procedures (SOPs) during the same research period (2010−
2013). The clinical and pathological features of the subjects are
described in Table 1.
1H NMR Spectra of Urine Specimens from IC Patients and
Controls
Because analysis of urine metabolites is a promising, noninvasive
approach to study bladder disease, as shown with bladder
cancer,17 we investigated the metabolite proﬁle of the individual
urine samples using 1H NMR spectroscopy. An NMR
spectrometer equipped with a triple-resonance cryogenic probe
was used for the analysis. NMR-based metabolomics requires
relatively simple sample preparation and provides structural
information on metabolites. Our analysis and data requisition
resulted in a total of 4501 metabolites detected. The spectra
featured visually identiﬁable diﬀerences in the signal ranges of
6.5−7.5, 3.5−4.0, and 2.0−2.5 ppm, suggesting metabolic
diﬀerences between IC patients and controls (Figure 1).
To compensate for possible outliers within samples, principal
component analysis (PCA) was performed on the NMR spectral
data of the urine samples from patients and controls. The Perato
scaling method and division of the mean-centered data by the
square root of the standard deviation were used (Figure 2A). The
scores plot for partial least-squares (PLS) components showed
diﬀerentiation of the IC samples from controls with good
separation and dispersion (Figure 2B). We further attempted to
assess how accurately our predictive model ﬁt using the leave-
one-out cross-validation method (also called rotation estima-
tion) as well as randomized permutation. The observed statistic
of this analysis usingMetaboAnalyst software14 was signiﬁcant (p
= 0.012), suggesting that these signatures may signiﬁcantly
diﬀerentiate patients from healthy controls (Figure 2C).
Identiﬁcation of NMR Peaks Increased in IC Specimens
Given the above result, we tried to identify NMR signals
responsible for the diﬀerence. We sought to capture the most
signiﬁcantly and diﬀerentially detected NMR peaks and found
that there was a signiﬁcant diﬀerence in the NMR peak
distribution between IC and control specimens. On the basis
of multivariate statistical analysis, a total of 140 NMR peaks were
signiﬁcantly diﬀerent between IC and controls (FDR < 0.05)
(Figure 3).We then focused on theNMRpeaks that most heavily
contributed to the separation with respect to high correlation and
signal-to-noise ratio values. We selected the top 15 NMR peaks
based on the partial least-squares discriminant analysis (PLS-
DA) model using MetaboAnalyst software.14 NMR signals at
3.2485, 4.3505, 3.243, 2.9606, 2.2924, 3.2504, 3.0157, 3.0212,
2.9625, 4.4422, 0.7017, 4.3523, 4.3432, 9.2718, and 3.0102 ppm
are among the major factors separating the groups with high
correlation and intensity of signal (Figure 4A). These key
candidate metabolites contribute to the separation of patients
and controls with a coeﬃcient 0.7 or more (Figure 4A). Given
that a coeﬃcient 0.53 or above is considered to be statistically
signiﬁcant (with a correlation coeﬃcient of a risk of 5% or less),
levels of these top 15 NMR peaks are considered to be strongly
correlated to the IC group. Although the intensities of four NMR
peaks at 4.3505, 4.4422, 4.3523, and 4.3432 ppm were
signiﬁcantly decreased in the IC group, the intensities of the
other 11 peaks were increased in this group (Figure 4B). These
ﬁndings suggest that these top 15NMRpeaks would be useful for
further annotation and analysis.
Identiﬁcation of Diﬀerentially Expressed Metabolites in
Urine of IC Patients
Independent quantiﬁcation of the metabolites that were
upregulated in patients showed that 11 NMR peaks (e.g.,
3.2485 and 3.243 ppm) were signiﬁcantly upregulated in IC
patients (p < 0.05). Annotation of the NMR peaks was
performed using MeltDB, Chenomx, and MetaboloAnalyst
software. We were able to annotate several of the discriminant
peaks, including the most signiﬁcant peak at 3.2485 ppm, which
was identiﬁed as tyramine, a neuro-transmodulator related to
pain.18 Other NMR peaks, such as 3.243 and 2.924 ppm, were
also annotated to tyramine, and peaks at 3.0157 and 3.0212 ppm
were annotated to 2-oxoglutarate (Figure 5A). Figure 5B shows
the structures and relative abundance of tyramine and 2-
oxoglutarate. Urinary concentrations of 3.2485, 2.924, and 3.243
ppm (annotated as tyramine) and 3.0157 and 3.0212 ppm
(annotated as 2-oxoglutarate) were increased in the IC patient
group compared to that in controls (Figure 5C). An additional
LC−MS analysis was able to conﬁrm the NMR-based data and
showed that levels of tyramine and 2-oxoglutarate were
signiﬁcantly increased in urine specimens from IC patients
compared to that in controls (approximately 2-fold, p < 0.05)
(Figure 5D,E).
The ﬁndings above suggest that bladder cells may sense higher
level of metabolites, resulting in biological changes. We then
Table 1. Clinical and Pathological Features of Patients with IC
and Control Subjects
variables no. of patients (%) no. of controls (%)
no. 43 21




Grade (IPSS Symptom Score)
severe (>20) 16 (37.2) 0 (0)
modest (9−19) 17 (39.5) 6 (28.6)
mild (0−8) 10 (23.3) 15 (71.4)
Symptoms
frequency 31 (72.1) 2 (9.5)
urgency 28 (65.1) 2 (9.5)
discomfort 9 (20.9) 0 (0)
pain 17 (39.5) 0 (0)
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tested the eﬀects of tyramine and 2-oxoglutarate on cell
proliferation in the hTERT-immortalized urothelial cell line
TRT-HU1 (Figure 5F). To do this, TRT-HU1 cells were treated
with varying concentrations of tyramine or 2-oxoglutarate. 2-
Oxoglutarate, also known as α-ketoglutarate, is a key
intermediate in the Krebs cycle, which plays a role in amino
acid synthesis, nitrogen transport, and oxidation reactions. TRT-
HU1 bladder cell proliferation was suppressed in the presence of
2-oxoglutarate in a dose-dependent manner. This observation is
consistent with previous observations by other groups. Previous
Figure 1. 1H NMR spectra of urine samples derived from controls (Ctrl, A) and IC subjects (IC, B). Metabolite peaks were assigned as described in
Materials and Methods.
Figure 2. Diﬀerentiation of IC patients and healthy control groups using multivariate statistical analysis. (A) Principal component analysis (PCA)
showed a clear separation of NMR peaks between patients and matched control subjects. (B) Partial least-squares discriminant analysis (PLS-DA) score
plot of the IC and control groups. Red, control samples; green, IC patient samples. The model was established using three principal components. PLS-
DA analysis diﬀerentiated IC patients from controls. (C) For model evaluation, the class prediction results based on cross-model validation predictions
of the original labeling compared to the permuted data assessed using the separation distance. Histogram shows distribution of separation distance based
on permutated data. Red arrow indicates observed statistic (p = 0.012).
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reports suggest that 2-oxoglutarate exerts antitumor eﬀects by
inhibition of the cell cycle transition through regulation of p21
Waf1/Cip1, p27 Kip1, cyclin D1, and Rb.19 2-Oxoglutarate also
inhibits angiogenesis-related proteins, such as HIF-1α, eryth-
ropoietin, and VEGF, under hypoxic conditions in tumor cells.20
Bladder cell proliferation was not inﬂuenced by tyramine
treatment (data not shown).
We also found that four NMR peaks, including those at 4.3505
and 4.4422 ppm, were signiﬁcantly downregulated in patients
compared to normal controls (Figure 6A). Two NMR peaks, at
4.4422 and 4.444 ppm, were annotated as trigonelline. The
coeﬃcient of the 4.444 ppm peak was just below 0.7. Box plots
shown in Figure 6B suggest that levels of trigonelline might be
signiﬁcantly lower in urine samples of IC patients compared to
those of controls.
■ DISCUSSION
In this study, we report, to our knowledge, the ﬁrst global analysis
of metabolic patterns in urine specimens derived from IC
patients and healthy subjects. NMR-basedmetabolomics analysis
identiﬁed 140 NMR peaks, which collectively distinguished the
IC patient urinary proﬁle from that of controls. The PLS-DA
model using MetaboAnalyst software14 revealed that 15 NMR
peaks are signiﬁcantly changed in urine of IC patients. Levels of
tyramine and 2-oxoglutarate were signiﬁcantly increased in the
urine specimens from IC patients compared to those from
controls. These compounds may be associated with bladder
pathology; however, conﬁrmatory studies are necessary.
Our metabolomic data suggest that tyramine might be
concentrated in the urine of IC patients. Tyramine is a product
of tyrosine metabolism and, like other trace amines,21 is a neuro-
transmodulator.22 Tyramine is detectable in plasma, serum, and
urine, and the measured level is signiﬁcantly altered in certain
disorders characterized by pain, such as common headaches,
migraines, urticaria, irritable bowel syndrome, and joint
pain.18,23,24 Thus, our ﬁndings suggest the interesting possibility
that urine metabolites may elicit or reﬂect one’s pain perception
during bladder ﬁlling and discomfort associated with IC. A
speciﬁc class of tyramine receptor, the trace amine associated
Figure 3. Surface plots (2D and 3D) of 140 quantiﬁed NMR peaks in IC and control groups. Among 4501 detected NMR peaks in total, 140 peaks were
signiﬁcantly altered in IC patients compared to that in controls (FDR < 0.05) (left, 3D; right, 2D).
Figure 4. NMR spectra segregating IC from controls. (A) The major
contributing NMR signals identiﬁed by PLS-DA. The regression
coeﬃcients represent the highest contributing signals from which the
IC and control groups could be distinguished. (B) The colored boxes
indicate the relative concentrations of the corresponding metabolite in
each group. Red and green denote high and low concentrations,
respectively. The top 15 NMR peaks are considered to be signiﬁcantly
diﬀerent between the two groups based on their coeﬃcients (>70).
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receptor (TAAR1),25 is a G-protein coupled receptor (GPCR)
expressed in the brain with a wide distribution in other organs.26
One class of GPCR, the transient receptor potential (TRP)
channel family, has been shown to regulate urothelial sensory
perception and bladder function. TRPV (transient receptor
potential channel subfamily V), located in the urothelium,27 plays
a role in the bladder sensor web.28 Pharmacological antagonists
against TRPV reduce bladder hyperactivity and urinary
incontinence in mouse and rat cystitis models.29 In addition,
anticholinergic agents, which block the neurotransmitter
acetylcholine in the central and the peripheral nervous system,
have been shown to improve bladder cellular architecture and
provide relief from pain and urgency.30
In the current study, we also found that the relative
concentration of 2-oxoglutarate was increased in the urine of
IC patients. 2-Oxoglutarate (also called α-ketoglutarate), which
is an important player in the Krebs cycle, is known to be involved
in the cellular detoxiﬁcation of oxidative damage. Previous
Figure 5. Upregulated metabolites that could be used to segregate IC patients from normal subjects. (A) NMR peaks at 3.0212 and 3.0157 ppm were
annotated as 2-oxoglutarate, and those at 3.2485, 3.243, and 2.924 ppm were annotated as tyramine, using a 500MHz machine (VNMRS500) at Varian
Inc., Korea. No annotation was available for the other three peaks using our software. (B) Chemical structures of tyramine and 2-oxoglutarate are shown.
(C) NMR peaks indicating that candidate metabolites, tyramine and 2-oxoglutarate, were signiﬁcantly increased in IC patients compared to that in
controls. Wilcoxon rank sum test of the relative diﬀerence of the marker signals for the IC and control groups. All signals showed statistical signiﬁcance
with *FDR < 0.05 (tyramine, 3.2485 ppm; 2.924 ppm; 3.243 ppm, 2-oxoglutarate, 3.0157 ppm; 3.0212 ppm). (D, E) LC−MS analysis showed the
relative levels of two biomarker metabolites in urine from IC patients compared with those from controls. The bar graphs represent the relative peak area
on LC−MS analysis for tyramine (D) and 2-oxoglutarate (E). Statistical analysis was performed using Student’s t-test, and the resulting p-values are
indicated. Error bars represent standard error. (F) Biological eﬀects of 2-oxoglutarate on bladder cells. 2-Oxoglutarate treatment inhibited cell
proliferation. Proliferation of TRT-HU1 cells treated with varying doses of 2-oxoglutarate (0, 1, 10, or 25 mM)was measured over time (days 0, 1, 2, and
3). Cell proliferation was determined by crystal violet assay. *, p < 0.05 (Student’s t-test).
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research has shown that 2-oxoglutarate converts to citrate during
hypoxic states, resulting in cell growth and viability, suggesting
the possibility of an antiproliferative and antiangiogenesis
function of 2-oxoglutarate. However, no functional role of
urinary 2-oxoglutarate has been proposed in the setting of
bladder wall abnormalities or bladder diseases, and no
correlations have been previously described.
In summary, our ﬁndings indicate that urinary metabolites may
allow the segregation of IC patients from normal individuals and
may reﬂect the underlying biology of IC, which is still largely
unknown. Further attempts to validate the clinical relevance of
urinary metabolites may provide novel insights into the etiology
of IC and will identify urine metabolites as biomarkers of IC that
have the potential to be employed clinically.
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